Earlier this year, J&J, Eli Lilly and Sanofi all tried to tweak how they divvy out 340B savings, by paying cash rebates to hospitals after the providers prove their drug purchases are eligible for ...
In a Dec. 13 letter, the Health Resources & Services Administration said that if Sanofi proceeds with its plan, the company could be terminated from the 340B Drug Discount Program. The agency also ...
Sanofi has filed a lawsuit accusing the Biden ... it proceeded with plans to issue credits to hospitals covered by the 340B Drug Discount Program for medicines ordered at full price from a wholesaler.
Novartis sues HHS over rejection of a proposed 340B rebate model, arguing it enhances transparency and compliance while ...
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
The 340B program, once a lifeline for underserved communities, has become a case study in crony capitalism. Designed to help hospitals serving low-income patients by offering discounted ...
The 340B Drug Pricing Program is a federal lifeline for vulnerable and underserved communities across the U.S., and its importance in Orlando is profound. Created to allow health-care safety-net ...
In a Dec. 13 letter, the Health Resources & Services Administration said that if Sanofi proceeds with its plan, the company could be terminated from the 340B Drug Discount Program. The agency also ...
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback